Study Condition(s): Solid Tumor

A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

Study Alias: JLDA

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT03099109 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with LY3300054, an anti-programmed death ligand 1 (PD-L1) antibody, in participants with advanced relapsed/refractory solid tumors.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

Your participation could last up to 12 months depending on how you and your tumor respond
  • Participant must have an advanced solid tumor confirmed by histology or cytology
  • Phase 1a participant must submit an archived tumor tissue sample (if available)
  • Phase 1b participant must be willing to provide a new or recently obtained biopsy
  • Participant must have an estimated life expectancy of 12 weeks
  • Participant must not have symptoms of uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease that requires treatment occurring at the same time as the study treatment
  • Participant must not have received a live vaccine within 30 days before the first dose of study treatment
  • Female participant must not be pregnant, breastfeeding, or planning to become pregnant
  • Participant must not have active or chronic HIV, active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorders, or prior documented severe autoimmune or inflammatory disorders requiring immunosuppressive treatment
  • Participant must not have a bowel obstruction

Where to Participate

8 locations are currently available of 40 planned
Invalid Postal Code.
Please re-enter postal code.
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.